Overview

Obesity is a growing epidemic in the United States, and effective treatment of this chronic disease requires evidence-based implementation of treatment approaches. This activity will discuss best practices for approaching the person with obesity and individualizing obesity treatment plans. It will include weight loss pharmacotherapy and approaches to address and overcome barriers to weight loss.

Learning Objectives

  • Discuss the benefits of weight loss with persons who are candidates for medical management of obesity
  • Discuss weight loss goals and treatment options with people who are candidates for medical management of obesity

Faculty

Scott Kahan, MD, MPH, FTOS, DABOM

Endocrinology Clinical Pharmacy Specialist/CGM Program Coordinator
Endocrinology and Metabolism Institute
Cleveland Clinic Diabetes Center
Cleveland, OH

 

Disclosures

The following financial relationships have been disclosed by faculty.

Scott Kahan, MD, MPH, FTOS, DABOM

Consultant for Novo Nordisk and Vivus

 

Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.


CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Pri-Med Institute and the Institute for Medical and Nursing Education, Inc. Pri-Med Institute is accredited by the ACCME to provide continuing medical education for physicians.


Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AANP

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Pri-Med Institute and the Institute for Medical and Nursing Education, Inc. Pri-Med Institute is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 040308.


Designation Statement

This program has been approved for 0.38 contact hour of continuing education, which includes 0.19 hours of pharmacology.

Instructions for Obtaining Credit

To complete this activity, you will be asked a series of questions related to the content, and be provided with feedback for each question. For questions not answered correctly, you will have the opportunity to review them until you respond correctly and confidently. CME/CE credit will be available upon demonstration of competence and confidence across all questions.

MOC Credit Information

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 


Commercial Supporter

Novo Nordisk Inc.

Education Partner

Institute for Medical and Nursing Education, Inc.


Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.